WFDC10B inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the WFDC10B protein, a member of the whey acidic protein (WAP) domain family. The WFDC10B protein, like other WAP domain-containing proteins, is associated with the regulation of protease activity, particularly serine proteases. Proteases are enzymes involved in a variety of biological processes such as protein degradation, tissue remodeling, and immune system responses. The WAP domain, a conserved structural feature of this protein family, functions primarily to inhibit the activity of proteases, thereby controlling the proteolytic balance within cells and tissues. By targeting WFDC10B, inhibitors modulate the role of this protein in regulating protease activity, influencing broader proteolytic pathways that are essential for maintaining cellular and extracellular equilibrium.
The molecular mechanism of WFDC10B inhibitors involves binding to the WAP domain or other crucial regions of the WFDC10B protein, thereby preventing it from interacting with its target proteases. This inhibition disrupts the protease regulatory functions of WFDC10B, altering key cellular processes such as extracellular matrix breakdown, cell migration, and immune responses. Researchers utilize WFDC10B inhibitors as tools to investigate the specific roles of WFDC10B in regulating protease-mediated activities, providing insights into the biological significance of this protein within various physiological systems. By selectively blocking the activity of WFDC10B, these inhibitors allow for a more detailed exploration of how WAP domain-containing proteins contribute to the regulation of proteolysis and the maintenance of tissue homeostasis, offering valuable perspectives on the intricate balance of protease activity in biological processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, which impacts various cellular processes that might intersect with WFDC10B's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor, known for altering cellular signaling pathways that could have downstream effects on WFDC10B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A MEK inhibitor, potentially affecting the ERK/MAPK pathway, which could indirectly influence WFDC10B activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, potentially altering signaling pathways relevant to WFDC10B's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, which may modify signaling pathways indirectly affecting WFDC10B. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Inhibits V-ATPase, potentially impacting endosomal-lysosomal functioning, which could influence WFDC10B. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known to affect autophagy and lysosomal function, potentially influencing WFDC10B's cellular context. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Primarily an autophagy inhibitor, which may have an indirect effect on WFDC10B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another potent PI3K inhibitor, which may indirectly affect WFDC10B activity through intracellular signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, potentially influencing cytoskeletal dynamics relevant to WFDC10B's function. | ||||||